Factors | Covariate | Local control | Overall survival | ||
---|---|---|---|---|---|
HR (95% CI) | P value | HR (95% CI) | P value | ||
Local status | Controlled | – | – | reference |  |
 | Failed | – | – | 2.390 (1.839–3.106) | < 0.001 |
ECOG PS | 0 | – | – | reference |  |
 | 1 | – | – | 1.316 (1.059–1.635) | 0.013 |
 | 2–3 | – | – | 2.008 (1.405–2.869) | < 0.001 |
Primary lesion sites | Colorectum | reference | Â | reference | Â |
 | Lung | 0.413 (0.274–0.622) | < 0.001 | 0.936 (0.685–1.280) | 0.681 |
 | H&N | 0.194 (0.077–0.489) | < 0.001 | 0.905 (0.556–1.474) | 0.690 |
 | Oesophagus | 0.618 (0.306–1.248) | 0.179 | 1.650 (1.027–2.650) | 0.038 |
 | Others | 0.337 (0.208–0.546) | < 0.001 | 1.208 (0.863–1.691) | 0.270 |
Pathology of primary lesion | Adenoca. | – | – | reference |  |
SqCC | – | – | 1.525 (1.122–2.072) | 0.006 | |
 | Others | – | – | 1.291 (0.916–1.818) | 0.143 |
Oligometastatic state | Oligo-rec | – | – | reference |  |
 | Sync-oligo | – | – | 1.391 (0.988–1.960) | 0.058 |
 | Unclassified | – | – | 1.246 (0.905–1.714) | 0.177 |
Chemotherapy concurrent with SBRT | Yes | 1.969 (0.859–4.513) | 0.109 | – | – |
No | reference |  | – | – | |
Maximum tumour diameter | Per 1 cm | 1.297 (1.059–1.588) | 0.011 | 1.266 (1.131–1.417) | < 0.001 |
Dose calculation algorithm | Type A | reference |  | – | – |
 | Type B | 0.592 (0.410–0.856) | 0.005 | – | – |
 | Type C | 0.732 (0.371–1.445) | 0.368 | – | – |
BED10 at isocenter | Per 10 Gy | 0.912 (0.828–1.006) | 0.065 | – | – |
OTT of SBRT | Per 10 days | 0.610 (0.385–0.966) | 0.035 | – | – |